Mayo Clinic researchers have discovered an enzyme they say is tightly linked to how aggressive pancreatic cancer will be in a patient.
It also offers a number of possible future clinical advances, such as a way to gauge outcome in individual patients, and insight into potential therapy to shut down activity of the enzyme, known as Rac1b.
"The implication from our research is that Rac1b is activating unique pathways in pancreatic tumors that make this cancer aggressive. If we can therapeutically target that pathway, we may be able to have an impact on this very difficult-to-treat disease," says the study's senior investigator, Derek Radisky, Ph.D., a researcher with the Mayo Clinic Cancer Center in Jacksonville, Fla.
A potential drug target would have to be found within the cancer-causing pathways activated by Rac1b, since the enzyme is difficult to target because it is involved in many normal biological processes, Dr. Radisky says. He and his colleagues are now working to uncover how Rac1b ramps up pancreatic cancer progression.
The RAC1 superfamily of proteins — which play important regulatory roles in cell growth and cell movement — have been implicated in other cancers, such as melanoma and non-small cell lung cancer, but before this study, no one knew that one sub-form, Rac1b, played a role in pancreatic cancer.
The research team includes investigators from Mayo Clinic in Florida and Mayo Clinic SPORE in Pancreatic Cancer, one of three cancer centers in the U.S. to receive a Specialized Program of Research Excellence (SPORE) grant for pancreatic cancer from the National Cancer Institute. The Pancreatic Cancer SPORE is specifically committed to reducing the incidence and mortality of pancreatic cancer. The team began their research by investigating why pancreatic cancer cells produce matrix metalloproteinases (MMPs), enzymes that break down the sticky adhesion molecules that keep cells glued together in a tissue, or in a tumor. MMPs allow cancer cells to migrate away from a tumor.
"Most MMPs are made by cells that surround and support a tumor, not by the tumor itself, as we see in pancreatic cancer," Dr. Radisky says.
Using a combination of human tissue biopsies, novel transgenic animal models and cell culture studies, the researchers established a link between expression of MMP3 and activation of Rac1b. Then, using Mayo Clinic's large panel of human pancreatic cancer biopsies, the scientists found that expression levels of Rac1b were significantly associated with the cancer's prognosis.
The researchers verified their findings by treating cultured pancreatic cancer cells with recombinant MMP3. They found this was sufficient to induce Rac1b and increased cancer invasiveness.
"Pancreatic cancer is not uniformly aggressive — some patients have a relatively better outcome. This work allows us to hone in on those patients who don't do as well, and who would most benefit from more targeted therapies," Dr. Radisky says.
The study was supported by the National Cancer Institute (CA122086, CA154387, R01CA159222 and R01CA136754), and by the Mayo Clinic SPORE in Pancreatic Cancer (P50 CA102701).
About Mayo Clinic
Recognizing 150 years of serving humanity in 2014, Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit 150years.mayoclinic.org, MayoClinic.org or newsnetwork.mayoclinic.org/.
Kevin Punsky | idw - Informationsdienst Wissenschaft
An experimental Alzheimer's drug reverses genetic changes thought to spur the disease
04.05.2016 | Rockefeller University
Research points to a new treatment for pancreatic cancer
04.05.2016 | Purdue University
Using an ultra fast-scanning atomic force microscope, a team of researchers from the University of Basel has filmed “living” nuclear pore complexes at work for the first time. Nuclear pores are molecular machines that control the traffic entering or exiting the cell nucleus. In their article published in Nature Nanotechnology, the researchers explain how the passage of unwanted molecules is prevented by rapidly moving molecular “tentacles” inside the pore.
Using high-speed AFM, Roderick Lim, Argovia Professor at the Biozentrum and the Swiss Nanoscience Institute of the University of Basel, has not only directly...
If a person pushes a broken-down car alone, there is a certain effect. If another person helps, the result is the sum of their efforts. If two micro-particles are pushing another microparticle, however, the resulting effect may not necessarily be the sum their efforts. A recent study published in Nature Communications, measured this odd effect that scientists call “many body.”
In the microscopic world, where the modern miniaturized machines at the new frontiers of technology operate, as long as we are in the presence of two...
Researchers from the Max Planck Institute Stuttgart have developed self-propelled tiny ‘microbots’ that can remove lead or organic pollution from contaminated water.
Working with colleagues in Barcelona and Singapore, Samuel Sánchez’s group used graphene oxide to make their microscale motors, which are able to adsorb lead...
Neutron scattering and computational modeling have revealed unique and unexpected behavior of water molecules under extreme confinement that is unmatched by any known gas, liquid or solid states.
In a paper published in Physical Review Letters, researchers at the Department of Energy's Oak Ridge National Laboratory describe a new tunneling state of...
Honeycomb structures as the basic building block for industrial applications presented using holo pyramid
Researchers of the Alfred Wegener Institute (AWI) will introduce their latest developments in the field of bionic lightweight design at Hannover Messe from 25...
27.04.2016 | Event News
15.04.2016 | Event News
12.04.2016 | Event News
04.05.2016 | Physics and Astronomy
04.05.2016 | Physics and Astronomy
04.05.2016 | Materials Sciences